Guided TherapeuticsGTHP 18 EBIT per Share is $-0.03 as of Mar. 2026. GuruFocus rates GTHP with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Guided Therapeutics ranks better than 80.46% on this metric.
Guided Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03.
During the past 3 years, the average EBIT per Share Growth Rate was 33.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 27.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Guided Therapeutics's EBIT per Share or its related term are showing as below:
GTHP'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -94.6 Med: 33.7 Max: 95.8
Current: 33.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Guided Therapeutics was 95.80% per year. The lowest was -94.60% per year. And the median was 33.70% per year.
GTHP's 3-Year EBIT Growth Rate is ranked better than 80.46% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs GTHP: 33.70
Guided Therapeutics (OTCPK:GTHP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Guided Therapeutics EBIT per Share Related Terms
Guided Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Guided Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guided Therapeutics (GTHP) has a EBIT per Share of $-0.03 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Guided Therapeutics and its competitors. According to the industry distribution chart, Guided Therapeutics ranks #135 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 19.5%.
Is Guided Therapeutics' EBIT per Share too high?
Guided Therapeutics' current EBIT per Share is $-0.03. Based on the distribution chart, Guided Therapeutics ranks #135 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Guided Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' EBIT per Share compare to CTSO and IRIX?
According to the Medical Devices & Instruments industry distribution chart, Guided Therapeutics ranks #135 out of 691 companies for EBIT per Share. This places Guided Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Guided Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guided Therapeutics's current EBIT per Share is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current EBIT per Share of $-0.03. The current EBIT per Share is $-0.03. Guided Therapeutics' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current EBIT per Share is $-0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
18GF Score
Get the complete analysis for GTHP
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GTHP has been successfully added to your 
